ArticleOncology letters2023
Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with
Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Interlesional Heterogeneity of EGFR Mutations: A Systematic Review and Meta-analysis.Molecular diagnosis & therapy · 2026Pooled it
- Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Meta-analysis ofInternational journal of immunopathology and pharmacologyPooled it
- Optimal timing of stereotactic radiosurgery with first-line osimertinib in EGFR-mutant non-small cell lung cancer brain metastases: Immediate, early-consolidation and salvage strategies.Oncology letters · 2026Article
- Decoding the role of polyamine metabolism in lung adenocarcinoma prognosis: A triangulated approach combining transcriptome, single-cell and Mendelian randomization analyses.Oncology letters · 2026Article
- Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.Journal of clinical medicine · 2026Article
- Tyrosine kinase inhibitor toxicity in the treatment of non-small-cell lung cancer: A bibliometric analysis (2009-2025).Medicine · 2026Article
- Anti-tumor effects and mechanism of the histone demethylase inhibitor GSK-J4 in non-small cell lung cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.Molecular biology reports · 2025Review
- Prognostic Impact of Infectious Agents After Definitive Treatment in Non-Small Cell Lung Cancer.Cancers · 2025Article
- PFN1 Knockdown Aggravates Mitophagy to Retard Lung Adenocarcinoma Initiation and M2 Macrophage Polarization.Molecular biotechnology · 2025Article
- SIRT2 as a Potential Biomarker in Lung Adenocarcinoma: Implications for Immune Infiltration.Molecular biotechnology · 2025Article
- Investigating the frequencies of EGFR mutations and EGFR single nucleotide polymorphisms genotypes and their predictive role in NSCLC patients in Republic of Serbia.Molecular biology reports · 2025Article
- Difficulties in the diagnosis and treatment of axillary malignant triton tumors: A case report.Oncology letters · 2025Article
- Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis.Oncology letters · 2025Article
- AKAP12, mediated by transcription factor 21, inhibits cell proliferation, metastasis, and glycolysis in lung squamous cell carcinoma.Open life sciences · 2025Article
- Evaluation of the efficacy of PD‑1/PD‑L1 inhibitor plus bevacizumab and chemotherapy for the treatment of patients with driver gene‑negative advanced‑stage lung adenocarcinoma: A retrospective cohort study.Oncology letters · 2025Article
- EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study.Frontiers in genetics · 2025Article
- Exploring the therapeutic potential of rabdoternin E in lung cancer treatment: Targeting the ROS/p38 MAPK/JNK signaling pathway.Molecular medicine reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rash and diarrhea are common side effects of tyrosine kinase inhibitor (TKI) therapy administered to patients with non-small cell lung cancer (NSCLC). The polymorphisms of the epidermal growth factor receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.